

# PHARMING GROUP N.V.

ISIN: NL0010391025 WKN: 518940 Asset Class: **Stock**

## Company

2024/07/11 17:13:32



### Price

**0.81** EUR

**Difference** ▲ 2.81%(0.02)



## Contact Details

PHARMING GROUP NV Tel: +31-71-524-74-00  
 -- Fax: +  
 Darwinweg 24 Web: <http://www.pharming.com>  
 2333 CR Leiden E-mail: [info@pharming.com](mailto:info@pharming.com)

## Company Profile

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST®, Joenja®, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	286,373,000		260,014,000		219,349,000	
<b>Common stock capital</b>		6,942,000		7,035,000		6,532,000
<b>Fixed assets</b>	139,966,000		144,797,000		135,138,000	
<b>Equity capital of a company</b>		198,054,000		191,743,000		169,641,000
<b>Cash and cash equivalents</b>	55,891,000		194,476,000		168,968,000	
<b>Accrued liabilities</b>		0		0		0
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		70,581,000		55,936,000		41,128,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		157,703,000		157,131,000		143,718,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		0		0		145,000
<b>Total assets</b>	426,339,000	426,339,000	404,811,000	404,811,000	354,488,000	354,488,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	-	-	-
<b>Equity ratio</b>	46.45%	47.37%	47.86%
<b>Debt-equity ratio</b>	115.26%	111.12%	108.96%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	12.49%	8.17%	31.64%

# PHARMING GROUP N.V.

ISIN: NL0010391025 WKN: 518940 Asset Class: Stock

## Income statement

	2023	2022	2021
<b>Turnover</b>	226,910,000	195,648,000	168,252,000
<b>Net income</b>	-9,756,000	13,010,000	13,533,000
<b>EBIT</b>	-8,591,126	20,407,730	24,125,601
<b>Operating income before taxes</b>	-10,843,000	15,290,000	18,937,000
<b>Cash Flow</b>	-19,546,000	17,348,000	27,857,000
<b>Net interest income</b>	-2,252,000	-5,117,000	-5,187,000
<b>Research and development expenses</b>	60,144,000	48,458,000	56,868,000
<b>Income taxes</b>	-1,354,000	1,249,000	5,991,000
<b>Result from investments in subsidiaries, associates and other</b>	-267,000	-1,030,000	587,000
<b>Revenues per employee</b>	-	-	-

## Board of Directors

Richard Peters	Chairman of Supervisory Board
Jabine T. M. van der Meijs	Member of Supervisory Board
Mark Pykett	Member of Supervisory Board
Barbara Yanni	Member of Supervisory Board
Deborah Jorn	Member of Supervisory Board
Leonard Kruimer	Member of Supervisory Board
Steven Baert	Member of Supervisory Board

## Members of Management Board

Sijmen de Vries	Chairman of Managing Board
Anurag Relan	Member of Executive Committee
Jeroen Wakkerman	Member of Executive Committee
Mireille Sanders	Member of Executive Committee
Ruud van Outersterp	Member of Executive Committee
Stephen Toor	Member of Executive Committee